The company conducts business under
Healthcare sector and is part of
Biotechnology industry.
Opiant Pharmaceuticals holds a
performance score of 15 on a scale of zero to a hundred. The company holds a Beta of 0.0492, which implies not very significant fluctuations relative to the market. Let's try to break down what Opiant's beta means in this case. As returns on the market increase, Opiant Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Opiant Pharmaceuticals will be expected to be smaller as well. Although it is vital to follow
Opiant Pharmaceuticals current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing
price patterns. Our philosophy towards forecasting
future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and
technical indicators. To evaluate if Opiant Pharmaceuticals expected return of 1.08 will be sustainable into the future, we have found twenty-eight different
technical indicators, which can help you to check if the expected returns are sustainable. Use Opiant Pharmaceuticals
treynor ratio, as well as the
relationship between the expected short fall and
day median price to analyze future returns on Opiant Pharmaceuticals.
Volatility is a rate at which the price of Opiant Pharmaceuticals or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Opiant Pharmaceuticals may increase or decrease. In other words, similar to Opiant's
beta indicator, it measures the risk of Opiant Pharmaceuticals and helps estimate the fluctuations that may happen in a short period of time. So if prices of Opiant Pharmaceuticals fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our
technical analysis page.
How important is Opiant Pharmaceuticals's Liquidity
Opiant Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance Opiant Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Opiant Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Opiant Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Opiant Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Opiant Pharmaceuticals's total debt and its cash.
Breaking it down a bit more
Opiant Pharmaceuticals reported the previous year's revenue of 43.91
M. Net Income was 1.57
M with profit before overhead, payroll, taxes, and interest of 14.19
M.
Opiant Pharmaceuticals implied volatility may change after the gain
The standard deviation is down to 4.96 as of today. Opiant Pharmaceuticals shows above-average downside volatility for the selected time horizon. We advise investors to inspect Opiant Pharmaceuticals further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Opiant Pharmaceuticals future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Opiant Pharmaceuticals' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Opiant Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Opiant Pharmaceuticals Implied Volatility
Opiant Pharmaceuticals' implied volatility exposes the market's sentiment of Opiant Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Opiant Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Opiant Pharmaceuticals stock will not fluctuate a lot when Opiant Pharmaceuticals' options are near their expiration.
The Current Takeaway on Opiant Pharmaceuticals Investment
Whereas some firms under the biotechnology industry are still a bit expensive, Opiant Pharmaceuticals may offer a potential longer-term growth to private investors. To conclude, as of the 4th of December 2021, we believe that Opiant Pharmaceuticals is currently
fairly valued with
high odds of financial distress in the next two years. Our current 90 days buy-hold-sell advice on the firm is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Opiant Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com